Two acronyms that come up constantly in life sciences sound similar but actually govern completely different parts of the chain: GCP and GDP. Here's what they really mean, and why the distinction matters.
What is GCP?
Good Clinical Practice (GCP) is an international quality standard for clinical trials involving human participants. It defines the ethical and scientific standards for designing, conducting, recording, and reporting trials. At its core, GCP exists to protect the rights, safety, and wellbeing of trial participants while ensuring the resulting data is credible and reliable.
What is GDP?
Good Distribution Practice (GDP) covers a different stage entirely: the guidelines that ensure medicines keep their quality and integrity throughout the entire distribution chain. This includes temperature control, proper storage, careful transport, and full traceability. GDP is effectively the link between GMP-regulated manufacturing and the moment a medicine reaches the patient.
Why it matters
Both frameworks are overseen by regulators such as the EMA and, in the Netherlands, the IGJ (Inspectorate for Health and Youth Care). Non-compliance carries real consequences: delayed clinical trials, loss of a distribution license, or costly product recalls.
SIRE® Life Sciences connects organizations with consultants experienced in GCP, GDP, GMP, and other GxP guidelines, helping teams stay compliant at every stage.
This article originally appeared on the SIRE Life Sciences blog.
Top comments (0)